BioEclipse Therapeutics is a clinical-stage biopharmaceutical company led by founder and CEO Pamela Contag, Ph.D., focused on delivering curative immuno-oncology therapeutics. Its lead product, CRX-100, is a patented, first in class, intravenously delivered targeted immunotherapy being developed against solid tumors, including some rare pediatric cancers. The company is preparing to initiate Phase 1b/2a clinical trials of CRX-100 in therapy-refractory solid tumors. BioEclipse announced a $7.7M Series A-1 financing and plans to use the proceeds to advance CRX-100 into those clinical studies. The financing brought total funding raised to date to $9.3M. The company also added three new board members: Mark Frohlich, MD (former EVP at Juno Therapeutics); Elona Baum (Managing Director, DEFTA Partners); and Oliver Hopkinson (Co‑Founder and Manager, Revelis Capital Group).

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2019